Quick answer
IgA nephropathy is the most common primary glomerulonephritis worldwide and a leading cause of kidney failure in young Chinese adults, with no disease-specific therapy for most of the last fifty years. Telitacicept, a Chinese-developed dual inhibitor of BLyS and APRIL, reduced proteinuria by 58.9% over 39 weeks in the phase III TELIGAN trial — a 55% placebo-corrected reduction — with stable kidney function. The results appeared in the New England Journal of Medicine on 14 May 2026 [1][2][4].
Key takeaways
- 318 biopsy-proven IgA nephropathy patients at high progression risk across 72 Chinese centres [2][5].
- Randomised, double-blind, placebo-controlled; telitacicept 240 mg subcutaneously weekly versus placebo for 39 weeks (stage A) [5].
- Proteinuria reduction 58.9%, placebo-corrected 55% [2].
- Kidney function remained stable; stage B will follow patients to 104 weeks [5].
- Published alongside parallel US and European trials of related agents [1][2].
Why this target
IgA nephropathy is driven by galactose-deficient IgA1: the body produces abnormal IgA1, makes antibodies against it, and the resulting immune complexes deposit in the glomerulus and trigger inflammation. Telitacicept blocks two cytokines — BLyS and APRIL — that keep B cells and plasma cells alive, reducing the production of that abnormal IgA1 at source [5].
This is a different strategy from the field's previous mainstays — corticosteroids and supportive care with RAS blockers — which reduce inflammation or its consequences but not the abnormal antibody production [2][5]. The earlier work from the same group established reduced-dose steroid regimens and hydroxychloroquine as options, both later reflected in KDIGO guidance; telitacicept adds a mechanism aimed at the upstream immune trigger rather than its downstream damage [2].
What the trial found
Proteinuria, the accepted surrogate for progression in IgA nephropathy, fell by more than half, and the effect exceeded the 30–50% reductions that current guidelines treat as meaningful. Kidney function stayed stable over the 39-week treatment period. The team describes the efficacy as best-in-class among the agents reported together [1][2].
Proteinuria is a surrogate; whether telitacicept preserves kidney function over years is what stage B will show. Blocking B-cell survival raises questions about infection risk, and the paper's safety data need to be read alongside the efficacy. The trial was conducted entirely in China, and the drug is now marketed there, with the first prescription written in July 2026 [3][5].
The condition in context: IgA nephropathy
It is common, silent for years, and disproportionately affects young adults.
| Region | What the data shows | Source |
|---|---|---|
| Progression | More than 70% of patients progress to kidney failure within 20 years [2]. | PKU First Hospital [2] |
| China | It is the commonest cause of kidney failure in young Chinese adults [2]. | PKU First Hospital [2] |
| Treatment gap | For five decades there was no specific therapy [2]. | PKU First Hospital [2] |
Because patients are young, decades of dialysis or transplant are at stake, making a disease-modifying drug valuable even at substantial cost [2][3].
Why it matters
| Potential | What the report suggests | Source |
|---|---|---|
| Efficacy | 58.9% proteinuria reduction, 55% placebo-corrected [2]. | [2] |
| Mechanism | Targets the source of abnormal IgA1 rather than downstream inflammation [5]. | [5] |
| Caution | Surrogate endpoint; long-term kidney outcomes pending [1]. | [1] |
Availability and limits
- This is an editorial summary of the publication and hospital reports, not medical advice [1][2].
- Proteinuria is a surrogate; hard outcomes are still being followed [5].
- Immunosuppression carries infection risk [3].
- The trial was conducted in China; applicability elsewhere needs confirmation [2].
- Cost and reimbursement are significant barriers [3].
What to ask before booking
| Question | Why it matters |
|---|---|
| Is my proteinuria high enough to warrant disease-specific therapy? | Guidelines use proteinuria thresholds [2]. |
| What is my infection risk on B-cell targeted therapy? | Immunosuppression requires monitoring [3]. |
| Which department handles foreign patients, and in what language? | PKU First Hospital is a working hospital we do not book; confirm international-department coordination and language support. |
| How will kidney function be tracked long term? | Surrogate gains must translate into function [5]. |
Questions patients ask
What is telitacicept?
A Chinese-developed dual inhibitor of BLyS and APRIL that reduces B-cell and plasma-cell survival, lowering production of the abnormal IgA1 that drives IgA nephropathy [5].
What did TELIGAN show?
In 318 patients, 39 weeks of telitacicept reduced proteinuria by 58.9% (55% placebo-corrected) with stable kidney function [2].
Where was it published?
The New England Journal of Medicine, online 14 May 2026, alongside two parallel international trials [1][2].
Does it prevent kidney failure?
Not yet demonstrated — proteinuria is a surrogate and longer follow-up is ongoing [5].
Is this relevant to international patients?
It is useful context for China's nephrology research. PKU First Hospital is a working hospital we do not book — contact it directly [1].